The Effects of Re-vitrectomy and Intravitreal anti-VEGF Treatments on Visual Outcome in Diabetic Vitreous Hemorrhage After Pars Plana Vitrectomy
Retina-Vitreus, cilt.32, sa.1, ss.30-35, 2023 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 32 Sayı: 1
- Basım Tarihi: 2023
- Doi Numarası: 10.37845/ret.vit.2023.32.5
- Dergi Adı: Retina-Vitreus
- Derginin Tarandığı İndeksler: Scopus, Academic Search Premier, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.30-35
- Anahtar Kelimeler: Anti-VEGF therapy, diabetic retinopathy, re-vitrectomy, visual outcomes, vitreous hemorrhage
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Purpose: This study analyzed the effects of re-vitrectomy and intravitreal anti-VEGF treatments and other factors on visual acuity in vitreous hemorrhages (VH) in diabetic patients after vitrectomy. Materials and Methods: VHs seen in vitrectomized diabetic patients were reviewed retrospectively. Hemorrhages in post vitrectomy diabetic vitreous hemorrhage (PDVH) were classified in three groups as moderate, marked and severe. One group of patients was treated with re-PPV, and the other had intravitreal anti-VEGF. Best-corrected visual acuity (BCVA), HbA1C levels, and anti-VEGF treatments up to the development of VH were evaluated during the one-year follow-up of the patients. Results: A total of 16 patients with PDVH (10 females and six males) were examined. Ten (62.5%) patients were treated with anti-VEGF and 6 (37.5%) with re-PPV. The mean age of the patients was 63.5±8.9 years, and there was no difference between the two treatment groups in terms of age (p=0.087), HbA1c (p=0.609), previous anti-VEGF treatments (p=0.488), and VH severity (p=0.091). A statistically significant difference was found between the baseline visual acuity values between the groups (p=0.016). The mean of the anti-VEGF group was 0.96 logMAR, while the mean of the re-PPV group was 1.33 logMAR (worse). There was no difference between the mean visual outcomes of the two groups at the end of six months (p=0.157) and one year (p=0.309). Conclusion: Since there was no difference between the two treatment modalities in terms of change in BCVA, minimally invasive intravitreal anti-VEGF therapy seems to be an alternative to re-vitrectomy in the treatment of PDVH.